logo

The Week In Review: Deals And Collaborations
By: China Bio Today   Saturday, October 17, 2009 5:01 PM

Vote for next session
The next market session will close:

The news from China life science last week was replete with stories about deals and investments, some of them involving sizable financial commitments while others pooled competencies. All built on the strengths of the respective organizations with the hope of creating something even more significant in the future.

In a surprising "teaser" story postdated to Monday, October 19, 2009, The California Institute for Regenerative Medicine (CIRM) revealed it has signed an agreement to collaborate on stem cell research with China's Ministry of Science and Technology (see story). The announcement was little more than a headline, leaving details to a more complete disclosure that will be released on Monday. CIRM has a mandate to spend $3 billion over ten years on stem cell research, though the money is restricted to entities that are domiciled in California.

In a similarly preliminary announcement, ChinaSF, the San Francisco agency in charge of building bridges between the US city and China businesses of all sectors, has signed a Memorandum of Understanding with China Medical City of Taizhou, Jiangsu Province. Under the agreement, which is expected to be signed in November, China Medical City will open an office and drug development facilities in San Francisco's Mission Bay business development project. San Francisco hopes that some of the 200 life science companies in China Medical City will eventually open facilities in San Francisco as well. Greg Scott, our Executive Editor, reports further that ChinaSF also visited Beijing, Suzhou and Zhangjiang Hi-Tech Park in Shanghai, as he was there for the discussions.

China Pediatric Pharmaceuticals (OTCBB: LHSI) has completed a reverse merger, taking over the company formerly known as Lid Hair Studios International (see story). China Pediatric Pharma, which is headquartered in Xi'an, produces and distributes prescription and OTC drugs for children, some of which are western while the rest are based on TCM. The company reported $7.1 million in revenue and $1.6 million in net income for the six months of 2009.

Next Page >>123

(0)
No Comments
Post Comment
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
   
 
 
 
 
   
 

The above story is the opinion of the author only and it does not reflect iStockAnalyst opinion. Further, the author is not personally advising you regarding the suitability of the story for your investment needs. In no event iStockAnalyst will be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from or arising out of, or in connection with the use of this information. Please consult your investment advisor before making any investment decision.
  
Advertisement
Popular Articles
Related Press Releases
Advertisement
Partner Center
Recent Articles by China Bio Today



Subscribe to Email Alerts rss feed or RSS feeds rss feed for articles from more than 500 contributors, press releases, SEC filings and full text news from more than four thousand sources.
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia